Wiele, A. J., Bathala, T. K., Hahn, A. W., Xiao, L., Duran, M., Ross, J. A., . . . Tannir, N. M. (2021). Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor‐Tyrosine Kinase Inhibitor Therapies. Oncologist.
Citación estilo ChicagoWiele, Andrew J., et al. "Lenvatinib With or Without Everolimus in Patients With Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor‐Tyrosine Kinase Inhibitor Therapies." Oncologist 2021.
Cita MLAWiele, Andrew J., et al. "Lenvatinib With or Without Everolimus in Patients With Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor‐Tyrosine Kinase Inhibitor Therapies." Oncologist 2021.